skip to content

Collaboration and Impact

 

See how we translate our basic research into impact success stories.

Read more at: Aqdot

Aqdot

Aqdot has revolutionised the encapsulation market.


Read more at: Astex

Astex

Astex' fragment-based approach to the discovery of small molecule drugs is used by many major pharma companies.


Read more at: Cambridge Epigenetix
Shankar Balasubramanian in lab

Cambridge Epigenetix

Cambridge Epigenetix has used research into the role of the epigenome in disease to develop a non-invasive diagnostic kit for widespread cancer screening.


Read more at: Fluidic Analytics

Fluidic Analytics

Fluidic Analytics is changing the way that protein analysis is conducted in industrial, academic and clinical settings.


Read more at: Impossible Materials
Professor Silvia Vignolini sitting at desk and smiling at camera

Impossible Materials

A low-cost, sustainable way to create bright white pigment without using damaging chemicals such as titanium dioxide.


Read more at: Nyobolt
Professor Clare Grey standing next to an NMR machine

Nyobolt

Nyobolt is supercharging the electric revolution with its ultra-fast charging batteries.


Read more at: PharmEnable

PharmEnable

PharmEnable uses advanced medicinal chemistry and artificial intelligence to design potential drug therapies.


Read more at: Solexa Sequencing

Solexa Sequencing

An after-work beer at the Panton Arms was the start of a DNA revolution.


Read more at: Sphere Fluidics

Sphere Fluidics

Sphere Fluidics' microdroplet technology is set to automate the discovery of therapeutic monoclonal antibodies, and transform how the biopharmaceutical industry works in this area.


Read more at: Xampla

Xampla

Xampla's goal is to eradicate the need for single-use plastics.


Read more at: Early stage spin-outs

Early stage spin-outs

University programmes like Cambridge Enterprise and Accelerate are helping us to spin-out and nurture the ideas of our researchers and students into beneficial and practicable applications.